Video

Dr. Jänne on Biomarker Results From a Study of AZD9291

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses biomarker results from the AURA study of AZD9291.

In this trial, patients were biopsied at baseline and then at Day 15. Interestingly, Jänne says, in many patients, there was not a sufficient amount of tumor cells remaining to analyze. The protocol was amended to allow for biopsies earlier than Day 15, but even then, many patients did not have evaluable tissue. The response rate was higher in those patients who could not have their tissue analyzed compared with those who could, Jänne says. This creates a possible hypothesis that residual tumor cells at a certain time point could indicate a less durable benefit.

In a subset of patients where analyses were possible, there was a biomarker modulation — phospho-EGFR went down, downstream signaling went down, PD-L1 expression went down and there was a corresponding increase in immune cell infiltrates. These findings matched what was predicted following preclinical models.

<<<

View more from the 2015 World Conference on Lung Cancer

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Noman Ashraf, MD
Ivy Riano, MD, of Dartmouth Geisel School of Medicine
Daniel E. Haggstrom, MD
Daniel E. Haggstrom, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.